Determination of Regulatory Review Period for Purposes of Patent Extension; Vandetanib, 33562-33563 [2014-13567]
Download as PDF
<![CDATA[
ehiers on DSK2VPTVN1PROD with NOTICES
33562
Federal Register / Vol. 79, No. 112 / Wednesday, June 11, 2014 / Notices
https://health.gov/dietaryguidelines/
2010.asp.
4. ‘‘Report of the Dietary Guidelines Advisory
Committee on the Dietary Guidelines for
Americans,’’ 2010 to the Secretary of
Agriculture and the Secretary of Health
and Human Services, available at https://
www.cnpp.usda.gov/DGAs2010DGACReport.htm.
5. FAO/WHO, (2011). ‘‘Report of the Joint
FAO/WHO Expert Consultation on the
Risks and Benefits of Fish
Consumption,’’ Rome, 25–29 January
2010. FAO Fisheries and Aquaculture
Report No. 978 FIPM/R978(En).
6. ‘‘A Quantitative Assessment of the Net
Effects on Fetal Neurodevelopment From
Eating Commercial Fish (As Measured by
IQ and also by Early Age Verbal
Development in Children).’’ Available at:
https://www.fda.gov/Food/
FoodborneIllnessContaminants/Metals/
ucm393211.htm.
7. Cohen, J.T., DC Bellinger, W.E. Connor, et
al., (November 2005). ‘‘A Quantitative
Risk-Benefit Analysis of Changes in
Population Fish Consumption,’’
American Journal of Preventive
Medicine, vol. 29(4), pp. 325–334.
8. Ginsberg, C.L. and B.F. Toal, (2009).
Quantitative Approach for Incorporating
Methylmercury Risks and Omega-3 Fatty
Acid Benefits in Developing SpeciesSpecific Fish Consumption Advice.
Environmental Health Perspectives, vol.
117(2), pp. 267–275.
`
9. Lando, A.M., S.B. Fein, and C.J. Choiniere,
(2012). ‘‘Awareness of Methylmercury in
Fish and Fish Consumption Among
Pregnant and Postpartum and Women of
Childbearing Age in the United States,’’
Environmental Research, vol. 116, pp.
85–92.
10. Daniels, J.L., M.P. Longnecker, A.S.
Rowland, J. Golding, and the ALSPAC
Study Team University of Bristol
Institute of Child Health, (July 2004).
‘‘Fish Intake During Pregnancy and Early
Cognitive Development of Offspring,’’
Epidemiology, vol. 15(4), pp. 394–402.
11. FAO/WHO, (2011). ‘‘Report of the Joint
FAO/WHO Expert Consultation on the
Risks and Benefits of Fish
Consumption,’’ Rome, January 25–29,
2010. FAO Fisheries and Aquaculture
Report No. 978 FIPM/R978(En) (see page
26).
12. Institute of Medicine, Committee on
Nutrient Relationships in Seafood:
‘‘Selections to Balance Benefits and
Risks,’’ (2006). Seafood Choices,
Balancing Benefits and Risks. The
National Academies Press, Washington,
DC. (see page 240).
13. ‘‘Mercury Levels in Commercial Fish and
Shellfish 1990–2010,’’ available at:
https://www.fda.gov/Food/
FoodborneIllnessContaminants/Metals/
ucm115644.htm.
Dated: June 6, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014–13584 Filed 6–10–14; 8:45 am]
BILLING CODE 4160–01–P
VerDate Mar<15>2010
17:31 Jun 10, 2014
Jkt 232001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2011–E–0713]
Determination of Regulatory Review
Period for Purposes of Patent
Extension; Vandetanib
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) has determined
the regulatory review period for
VANDETANIB and is publishing this
notice of that determination as required
by law. FDA has made the
determination because of the
submission of an application to the
Director of the U.S. Patent and
Trademark Office (USPTO) for the
extension of a patent which claims that
human drug product.
ADDRESSES: Submit electronic
comments to https://
www.regulations.gov. Submit written
petitions (two copies are required) and
written comments to the Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
Submit petitions electronically to
https://www.regulations.gov at Docket
No. FDA–2013–S–0610.
FOR FURTHER INFORMATION CONTACT:
Beverly Friedman, Office of
Management, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 6257,
Silver Spring, MD 20993–0002, 301–
796–7900.
SUPPLEMENTARY INFORMATION: The Drug
Price Competition and Patent Term
Restoration Act of 1984 (Pub. L. 98–417)
and the Generic Animal Drug and Patent
Term Restoration Act (Pub. L. 100–670)
generally provide that a patent may be
extended for a period of up to 5 years
so long as the patented item (human
drug product, animal drug product,
medical device, food additive, or color
additive) was subject to regulatory
review by FDA before the item was
marketed. Under these acts, a product’s
regulatory review period forms the basis
for determining the amount of extension
an applicant may receive.
A regulatory review period consists of
two periods of time: A testing phase and
an approval phase. For human drug
products, the testing phase begins when
the exemption to permit the clinical
investigations of the drug becomes
effective and runs until the approval
SUMMARY:
PO 00000
Frm 00071
Fmt 4703
Sfmt 4703
phase begins. The approval phase starts
with the initial submission of an
application to market the human drug
product and continues until FDA grants
permission to market the drug product.
Although only a portion of a regulatory
review period may count toward the
actual amount of extension that the
Director of USTPO may award (for
example, half the testing phase must be
subtracted as well as any time that may
have occurred before the patent was
issued), FDA’s determination of the
length of a regulatory review period for
a human drug product will include all
of the testing phase and approval phase
as specified in 35 U.S.C. 156(g)(1)(B).
FDA has approved for marketing the
human drug product Vandetanib.
Vandetanib is indicated for the
treatment of symptomatic or progressive
medullary thyroid cancer in patients
with unresectable locally advanced or
metastatic disease. Subsequent to this
approval, the USPTO received a patent
term restoration application for
Vandetanib (U.S. Patent No. RE42,353)
from AstraZeneca UK Limited, and the
USPTO requested FDA’s assistance in
determining this patent’s eligibility for
patent term restoration. In a letter dated
July 9, 2012, FDA advised the USTPO
that this human drug product had
undergone a regulatory review period
and that the approval of Vandetanib
represented the first permitted
commercial marketing or use of the
product. Thereafter, the USPTO
requested that FDA determine the
product’s regulatory review period.
FDA has determined that the
applicable regulatory review period for
Vandetanib is 4,009 days. Of this time,
3,735 days occurred during the testing
phase of the regulatory review period,
while 274 days occurred during the
approval phase. These periods of time
were derived from the following dates:
1. The date an exemption under
section 505(i) of the Federal Food, Drug,
and Cosmetic Act (the FD&C Act) (21
U.S.C. 355(i)) became effective: April
16, 2000. The applicant claims April 20,
2000, as the date the investigational new
drug application (IND) became effective.
However, FDA records indicate that the
IND effective date was April 16, 2000,
which was 30 days after FDA receipt of
the IND.
2. The date the application was
initially submitted with respect to the
human drug product under section
505(b) of the FD&C Act: July 7, 2010.
FDA has verified the applicant’s claim
that the new drug application (NDA) for
Vandetanib (NDA 22–405) was
submitted on July 7, 2010.
3. The date the application was
approved: April 6, 2011. FDA has
E:\FR\FM\11JNN1.SGM
11JNN1
Federal Register / Vol. 79, No. 112 / Wednesday, June 11, 2014 / Notices
verified the applicant’s claim that NDA
22–405 was approved on April 6, 2011.
This determination of the regulatory
review period establishes the maximum
potential length of a patent extension.
However, the USPTO applies several
statutory limitations in its calculations
of the actual period for patent extension.
In its application for patent extension,
this applicant seeks 1,738 days of patent
term extension.
Anyone with knowledge that any of
the dates as published are incorrect may
submit to the Division of Dockets
Management (see ADDRESSES) either
electronic or written comments and ask
for a redetermination by August 11,
2014. Furthermore, any interested
person may petition FDA for a
determination regarding whether the
applicant for extension acted with due
diligence during the regulatory review
period by December 8, 2014. To meet its
burden, the petition must contain
sufficient facts to merit an FDA
investigation. (See H. Rept. 857, part 1,
98th Cong., 2d sess., pp. 41–42, 1984.)
Petitions should be in the format
specified in 21 CFR 10.30.
Interested persons may submit to the
Division of Dockets Management (see
ADDRESSES) electronic or written
comments and written or electronic
petitions. It is only necessary to send
one set of comments. Identify comments
with the docket number found in
brackets in the heading of this
document. If you submit a written
petition, two copies are required. A
petition submitted electronically must
be submitted to https://
www.regulations.gov, Docket No. FDA–
2013–S–0610. Comments and petitions
that have not been made publicly
available on https://www.regulations.gov
may be viewed in the Division of
Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday.
Dated: June 5, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014–13567 Filed 6–10–14; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
ehiers on DSK2VPTVN1PROD with NOTICES
[Docket No. FDA–2011–E–0714]
Determination of Regulatory Review
Period for Purposes of Patent
Extension; Vandetanib
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
VerDate Mar<15>2010
15:19 Jun 10, 2014
Jkt 232001
The Food and Drug
Administration (FDA) has determined
the regulatory review period for
Vandetanib and is publishing this notice
of that determination as required by
law. FDA has made the determination
because of the submission of an
application to the Director of Patents
and Trademarks, Department of
Commerce, for the extension of a patent
which claims that human drug product.
ADDRESSES: Submit electronic
comments to https://
www.regulations.gov. Submit written
petitions (two copies are required) and
written comments to the Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
Submit petitions electronically to
https://www.regulations.gov at Docket
No. FDA–2013–S–0610.
FOR FURTHER INFORMATION CONTACT:
Beverly Friedman, Office of
Management, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 6257,
Silver Spring, MD 20993–0002, 301–
796–7900.
SUPPLEMENTARY INFORMATION: The Drug
Price Competition and Patent Term
Restoration Act of 1984 (Pub. L. 98–417)
and the Generic Animal Drug and Patent
Term Restoration Act (Pub. L. 100–670)
generally provide that a patent may be
extended for a period of up to 5 years
so long as the patented item (human
drug product, animal drug product,
medical device, food additive, or color
additive) was subject to regulatory
review by FDA before the item was
marketed. Under these acts, a product’s
regulatory review period forms the basis
for determining the amount of extension
an applicant may receive.
A regulatory review period consists of
two periods of time: A testing phase and
an approval phase. For human drug
products, the testing phase begins when
the exemption to permit the clinical
investigations of the drug becomes
effective and runs until the approval
phase begins. The approval phase starts
with the initial submission of an
application to market the human drug
product and continues until FDA grants
permission to market the drug product.
Although only a portion of a regulatory
review period may count toward the
actual amount of extension that the
Director of Patents and Trademarks may
award (for example, half the testing
phase must be subtracted as well as any
time that may have occurred before the
patent was issued), FDA’s determination
of the length of a regulatory review
period for a human drug product will
SUMMARY:
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
33563
include all of the testing phase and
approval phase as specified in 35 U.S.C.
156(g)(1)(B).
FDA has approved for marketing the
human drug product Vandetanib
(vandetanib). Vandetanib is indicated
for the treatment of symptomatic or
progressive medullary thyroid cancer in
patients with unresectable locally
advanced or metastatic disease.
Subsequent to this approval, the Patent
and Trademark Office received a patent
term restoration application for
Vandetanib (U.S. Patent No. 7,173,038)
from AstraZeneca AB, and the Patent
and Trademark Office requested FDA’s
assistance in determining this patent’s
eligibility for patent term restoration. In
a letter dated July 9, 2012, FDA advised
the Patent and Trademark Office that
this human drug product had undergone
a regulatory review period and that the
approval of Vandetanib represented the
first permitted commercial marketing or
use of the product. Thereafter, the
Patent and Trademark Office requested
that FDA determine the product’s
regulatory review period.
FDA has determined that the
applicable regulatory review period for
Vandetanib is 4,009 days. Of this time,
3,735 days occurred during the testing
phase of the regulatory review period,
while 274 days occurred during the
approval phase. These periods of time
were derived from the following dates:
1. The date an exemption under
section 505(i) of the Federal Food, Drug,
and Cosmetic Act (the FD&C Act) (21
U.S.C. 355(i)) became effective: April
16, 2000. The applicant claims April 20,
2000, as the date the investigational new
drug application (IND) became effective.
However, FDA records indicate that the
IND effective date was April 16, 2000,
which was 30 days after FDA receipt of
the IND.
2. The date the application was
initially submitted with respect to the
human drug product under section
505(b) of the FD&C Act: July 7, 2010.
FDA has verified the applicant’s claim
that the new drug application (NDA) for
VANDETANIB (NDA 22–405) was
submitted on July 7, 2010.
3. The date the application was
approved: April 6, 2011. FDA has
verified the applicant’s claim that NDA
22–405 was approved on April 6, 2011.
This determination of the regulatory
review period establishes the maximum
potential length of a patent extension.
However, the Patent and Trademark
Office applies several statutory
limitations in its calculations of the
actual period for patent extension. In its
application for patent extension, this
applicant seeks 898 days of patent term
extension.
E:\FR\FM\11JNN1.SGM
11JNN1
]]>Agencies
[Federal Register Volume 79, Number 112 (Wednesday, June 11, 2014)]
[Notices]
[Pages 33562-33563]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-13567]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2011-E-0713]
Determination of Regulatory Review Period for Purposes of Patent
Extension; Vandetanib
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) has determined the
regulatory review period for VANDETANIB and is publishing this notice
of that determination as required by law. FDA has made the
determination because of the submission of an application to the
Director of the U.S. Patent and Trademark Office (USPTO) for the
extension of a patent which claims that human drug product.
ADDRESSES: Submit electronic comments to https://www.regulations.gov.
Submit written petitions (two copies are required) and written comments
to the Division of Dockets Management (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
Submit petitions electronically to https://www.regulations.gov at Docket
No. FDA-2013-S-0610.
FOR FURTHER INFORMATION CONTACT: Beverly Friedman, Office of
Management, Center for Drug Evaluation and Research, Food and Drug
Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6257, Silver
Spring, MD 20993-0002, 301-796-7900.
SUPPLEMENTARY INFORMATION: The Drug Price Competition and Patent Term
Restoration Act of 1984 (Pub. L. 98-417) and the Generic Animal Drug
and Patent Term Restoration Act (Pub. L. 100-670) generally provide
that a patent may be extended for a period of up to 5 years so long as
the patented item (human drug product, animal drug product, medical
device, food additive, or color additive) was subject to regulatory
review by FDA before the item was marketed. Under these acts, a
product's regulatory review period forms the basis for determining the
amount of extension an applicant may receive.
A regulatory review period consists of two periods of time: A
testing phase and an approval phase. For human drug products, the
testing phase begins when the exemption to permit the clinical
investigations of the drug becomes effective and runs until the
approval phase begins. The approval phase starts with the initial
submission of an application to market the human drug product and
continues until FDA grants permission to market the drug product.
Although only a portion of a regulatory review period may count toward
the actual amount of extension that the Director of USTPO may award
(for example, half the testing phase must be subtracted as well as any
time that may have occurred before the patent was issued), FDA's
determination of the length of a regulatory review period for a human
drug product will include all of the testing phase and approval phase
as specified in 35 U.S.C. 156(g)(1)(B).
FDA has approved for marketing the human drug product Vandetanib.
Vandetanib is indicated for the treatment of symptomatic or progressive
medullary thyroid cancer in patients with unresectable locally advanced
or metastatic disease. Subsequent to this approval, the USPTO received
a patent term restoration application for Vandetanib (U.S. Patent No.
RE42,353) from AstraZeneca UK Limited, and the USPTO requested FDA's
assistance in determining this patent's eligibility for patent term
restoration. In a letter dated July 9, 2012, FDA advised the USTPO that
this human drug product had undergone a regulatory review period and
that the approval of Vandetanib represented the first permitted
commercial marketing or use of the product. Thereafter, the USPTO
requested that FDA determine the product's regulatory review period.
FDA has determined that the applicable regulatory review period for
Vandetanib is 4,009 days. Of this time, 3,735 days occurred during the
testing phase of the regulatory review period, while 274 days occurred
during the approval phase. These periods of time were derived from the
following dates:
1. The date an exemption under section 505(i) of the Federal Food,
Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. 355(i)) became
effective: April 16, 2000. The applicant claims April 20, 2000, as the
date the investigational new drug application (IND) became effective.
However, FDA records indicate that the IND effective date was April 16,
2000, which was 30 days after FDA receipt of the IND.
2. The date the application was initially submitted with respect to
the human drug product under section 505(b) of the FD&C Act: July 7,
2010. FDA has verified the applicant's claim that the new drug
application (NDA) for Vandetanib (NDA 22-405) was submitted on July 7,
2010.
3. The date the application was approved: April 6, 2011. FDA has
[[Page 33563]]
verified the applicant's claim that NDA 22-405 was approved on April 6,
2011.
This determination of the regulatory review period establishes the
maximum potential length of a patent extension. However, the USPTO
applies several statutory limitations in its calculations of the actual
period for patent extension. In its application for patent extension,
this applicant seeks 1,738 days of patent term extension.
Anyone with knowledge that any of the dates as published are
incorrect may submit to the Division of Dockets Management (see
ADDRESSES) either electronic or written comments and ask for a
redetermination by August 11, 2014. Furthermore, any interested person
may petition FDA for a determination regarding whether the applicant
for extension acted with due diligence during the regulatory review
period by December 8, 2014. To meet its burden, the petition must
contain sufficient facts to merit an FDA investigation. (See H. Rept.
857, part 1, 98th Cong., 2d sess., pp. 41-42, 1984.) Petitions should
be in the format specified in 21 CFR 10.30.
Interested persons may submit to the Division of Dockets Management
(see ADDRESSES) electronic or written comments and written or
electronic petitions. It is only necessary to send one set of comments.
Identify comments with the docket number found in brackets in the
heading of this document. If you submit a written petition, two copies
are required. A petition submitted electronically must be submitted to
https://www.regulations.gov, Docket No. FDA-2013-S-0610. Comments and
petitions that have not been made publicly available on https://www.regulations.gov may be viewed in the Division of Dockets Management
between 9 a.m. and 4 p.m., Monday through Friday.
Dated: June 5, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014-13567 Filed 6-10-14; 8:45 am]
BILLING CODE 4160-01-P
